MX9702204A - Tratamiento con ribozimas de enfermedades o condiciones relacionadas con niveles de lipoproteina (a) [lp(a)] en plasma, inhibiendo apolipoproteina (a) [apo(a)]. - Google Patents

Tratamiento con ribozimas de enfermedades o condiciones relacionadas con niveles de lipoproteina (a) [lp(a)] en plasma, inhibiendo apolipoproteina (a) [apo(a)].

Info

Publication number
MX9702204A
MX9702204A MX9702204A MX9702204A MX9702204A MX 9702204 A MX9702204 A MX 9702204A MX 9702204 A MX9702204 A MX 9702204A MX 9702204 A MX9702204 A MX 9702204A MX 9702204 A MX9702204 A MX 9702204A
Authority
MX
Mexico
Prior art keywords
apo
levels
diseases
conditions related
plasma lipoprotein
Prior art date
Application number
MX9702204A
Other languages
English (en)
Other versions
MXPA97002204A (es
Inventor
Dan T Stichcomb
James Mcswiggen
Roger S Newton
Rendy Ramharack
Original Assignee
Ribozyme Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribozyme Pharm Inc filed Critical Ribozyme Pharm Inc
Publication of MXPA97002204A publication Critical patent/MXPA97002204A/es
Publication of MX9702204A publication Critical patent/MX9702204A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/122—Hairpin

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Moléculas enzimáticas de ARN que cortan ARNm de apo(a); uso de estas moléculas catalíticas de ARN para el tratamiento de condiciones relacionadas de ARN para el tratamiento de condiciones relacionadas con niveles de liporproteína A, tales como aterosclerosis, infarto al miocardio, ataques y enfermedades cardiacas.
MX9702204A 1994-09-23 1995-09-21 Tratamiento con ribozimas de enfermedades o condiciones relacionadas con niveles de lipoproteina (a) [lp(a)] en plasma, inhibiendo apolipoproteina (a) [apo(a)]. MX9702204A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08311760 1994-09-23
US08/311,760 US5599706A (en) 1994-09-23 1994-09-23 Ribozymes targeted to apo(a) mRNA
PCT/US1995/011995 WO1996009392A1 (en) 1994-09-23 1995-09-21 RIBOZYME TREATMENT OF DISEASES OR CONDITIONS RELATED TO LEVELS OF PLASMA LIPOPROTEIN (a) [Lp(a)] BY INHIBITING APOLIPOPROTEIN (a) [APO(a)]

Publications (2)

Publication Number Publication Date
MXPA97002204A MXPA97002204A (es) 1997-06-01
MX9702204A true MX9702204A (es) 1997-06-28

Family

ID=23208337

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9702204A MX9702204A (es) 1994-09-23 1995-09-21 Tratamiento con ribozimas de enfermedades o condiciones relacionadas con niveles de lipoproteina (a) [lp(a)] en plasma, inhibiendo apolipoproteina (a) [apo(a)].

Country Status (7)

Country Link
US (2) US5599706A (es)
EP (1) EP0782622A1 (es)
JP (1) JPH10506016A (es)
AU (1) AU3720295A (es)
CA (1) CA2199727A1 (es)
MX (1) MX9702204A (es)
WO (1) WO1996009392A1 (es)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19617851A1 (de) 1996-05-03 1997-11-13 Hoechst Ag Nukleinsäurekonstrukte mit Genen kodierend für Transportsignale
AU2100499A (en) * 1997-12-19 1999-07-12 Genetrace Systems, Inc. Non-bacterial cloning in delivery and expression of nucleic acids
ATE344322T1 (de) 1998-02-13 2006-11-15 Koester Hubert Verwendung von ribozymen zur bestimmung der funktion von genen
US6225063B1 (en) 1998-05-22 2001-05-01 University Technology Corporation RNA channels in biological membranes
ES2324540T3 (es) * 1998-05-27 2009-08-10 Genzyme Corporation Vectores aav para la fabricacion de medicamentos para la administracion potenciada por conveccion.
WO1999067400A1 (en) * 1998-06-24 1999-12-29 Musc Foundation For Research Development Tissue-specific and target rna-specific ribozymes
US6492111B1 (en) 1998-11-25 2002-12-10 Isis Pharmaceuticals, Inc. In situ binary synthesis of biologically effective molecules
EP1074634B1 (en) * 1999-07-09 2002-10-02 Institut Pasteur De Lille Method for the diagnosis or the prognosis of Alzheimer disease therapeutical composition for preventing or treating Alzheimer disease
WO2001012789A2 (en) * 1999-08-18 2001-02-22 Baylor College Of Medicine APOLIPOPROTEIN B mRNA-SPECIFIC RIBOZYME
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US7125660B2 (en) 2000-09-13 2006-10-24 Archemix Corp. Nucleic acid sensor molecules and methods of using same
US20030087239A1 (en) * 2000-09-13 2003-05-08 Marty Stanton Target activated nucleic acid biosensor and methods of using same
WO2002030465A2 (en) 2000-10-12 2002-04-18 University Of Rochester Compositions that inhibit proliferation of cancer cells
US7227014B2 (en) * 2001-08-07 2007-06-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein (a) expression
US7259150B2 (en) 2001-08-07 2007-08-21 Isis Pharmaceuticals, Inc. Modulation of apolipoprotein (a) expression
ATE469167T1 (de) 2002-02-06 2010-06-15 Vicor Technologies Inc Anti-infarkt-moleküle
EP1534729A2 (en) * 2002-02-26 2005-06-01 University of Utah Research Foundation Variants of nedd4l associated with hypertension and viral budding
AU2003223775A1 (en) * 2002-04-30 2003-11-17 Duke University Adeno-associated viral vectors and methods for their production from hybrid adenovirus and for their use
AU2003257181A1 (en) 2002-08-05 2004-02-23 University Of Rochester Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof
US20040052161A1 (en) * 2002-09-17 2004-03-18 Steven Liao Mechanical clock having wireless manipulation and adjustment function
IL296666A (en) 2005-03-23 2022-11-01 Genmab As Antibodies against 38cd for the treatment of multiple myeloma
US7476733B2 (en) * 2005-03-25 2009-01-13 The United States Of America As Represented By The Department Of Health And Human Services Development of a real-time PCR assay for detection of pneumococcal DNA and diagnosis of pneumococccal disease
CA2625349A1 (en) * 2005-10-06 2007-04-19 Emthrax, Llc Methods and compositions relating to anthrax spore glycoproteins as vaccines
US8080534B2 (en) * 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
EP2392646A1 (en) 2005-10-14 2011-12-07 MUSC Foundation For Research Development Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy
EP1981548A4 (en) * 2006-01-20 2010-03-24 Univ North Carolina ENHANCED PRODUCTION OF INFECTIOUS VECTORS OF PARVOVIRUS IN INSECT CELLS
AU2007297535C1 (en) 2006-09-21 2017-11-23 University Of Florida Research Foundation, Inc. Compositions and methods related to protein displacement therapy for myotonic distrophy
WO2008136852A2 (en) 2006-11-01 2008-11-13 University Of Rochester Methods and compositions related to the structure and function of apobec3g
KR20090089462A (ko) 2006-12-11 2009-08-21 유니버시티 오브 유타 리써치 파운데이션 병적 혈관형성 및 혈관 투과성을 치료하기 위한 조성물 및 방법
WO2009026496A1 (en) * 2007-08-22 2009-02-26 University Of Southern California Grp78 and tumor angiogenesis
US8557767B2 (en) 2007-08-28 2013-10-15 Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
DK2682400T5 (da) 2007-08-28 2017-11-27 Uab Research Foundation Syntetiske apolipoprotein E-efterlignende polypeptider og fremgangsmåder til anvendelse
EP2268664B1 (en) * 2007-12-03 2017-05-24 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Doc1 compositions and methods for treating cancer
US20090233993A1 (en) * 2008-03-06 2009-09-17 Burnham Institute For Medical Research Compositions and methods for inhibiting gsk3 activity and uses thereof
US20110262395A1 (en) 2008-05-08 2011-10-27 University Of Utah Research Foundation Sensory receptors for chronic fatigue and pain and uses thereof
AU2009281732A1 (en) * 2008-08-15 2010-02-18 Georgetown University Na channels, disease, and related assays and compositions
EP2370080A1 (en) 2008-12-02 2011-10-05 University of Utah Research Foundation Pde1 as a target therapeutic in heart disease
WO2010093784A2 (en) 2009-02-11 2010-08-19 The University Of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
US20100286762A1 (en) * 2009-03-18 2010-11-11 Musc Foundation For Research Development Compositions and Methods for Ameliorating Clinical Electrical Disturbances
WO2011031974A1 (en) 2009-09-10 2011-03-17 Southern Research Institute Acridine analogs in the treatment of gliomas
ES2683695T3 (es) 2010-01-12 2018-09-27 The University Of North Carolina At Chapel Hill Repeticiones terminales invertidas restrictivas para vectores virales
US20110207789A1 (en) 2010-02-19 2011-08-25 Ye Fang Methods related to casein kinase ii (ck2) inhibitors and the use of purinosome-disrupting ck2 inhibitors for anti-cancer therapy agents
EP2673289B1 (en) 2011-02-10 2023-05-03 The University of North Carolina At Chapel Hill Viral vectors with modified transduction profiles and methods of making and using the same
WO2013173789A2 (en) 2012-05-17 2013-11-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide compositions
US9574193B2 (en) 2012-05-17 2017-02-21 Ionis Pharmaceuticals, Inc. Methods and compositions for modulating apolipoprotein (a) expression
MX360639B (es) 2012-05-24 2018-11-12 Ionis Pharmaceuticals Inc Métodos y composiciones para modular la expresión de apolipoproteína (a).
PL2900686T3 (pl) 2012-09-28 2021-01-25 The University Of North Carolina At Chapel Hill Wektory aav ukierunkowane na oligodendrocyty
EP2970966A4 (en) 2013-03-15 2016-10-26 Univ North Carolina SYNTHETIC ADENOASSOZED VIRUS INVERTED REPEAT SEQUENCES
IL298049B2 (en) 2013-03-15 2023-10-01 Univ North Carolina Chapel Hill Methods and compounds for ligation of paired AAV glycan vectors
RU2019110030A (ru) 2013-05-01 2019-05-06 Ионис Фармасьютикалз, Инк. Композиции и способы
CA2954475C (en) 2014-07-31 2023-05-16 Uab Research Foundation Apoe mimetic peptides and higher potency to clear plasma cholesterol
RU2727015C2 (ru) 2014-11-21 2020-07-17 Дзе Юниверсити Оф Норт Каролина Эт Чепел Хилл Векторы aav, нацеленные на центральную нервную систему
CA2972807C (en) 2015-01-14 2024-01-16 The University Of North Carolina At Chapel Hill Methods and compositions for targeted gene transfer
KR102554850B1 (ko) 2015-02-06 2023-07-13 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 최적화된 인간 응고 인자 viii 유전자 발현 카세트 및 그의 용도
EP3258961A4 (en) 2015-02-20 2018-08-22 Board of Regents, The University of Texas System Methods and compositions for attenuated chlamydia as vaccine and vector
SG10202107733QA (en) 2015-09-28 2021-09-29 Univ North Carolina Chapel Hill Methods and compositions for antibody-evading virus vectors
JOP20210043A1 (ar) 2015-10-01 2017-06-16 Arrowhead Pharmaceuticals Inc تراكيب وأساليب لتثبيط تعبير جيني للـ lpa
KR20180073606A (ko) 2015-11-06 2018-07-02 아이오니스 파마수티컬즈, 인코포레이티드 아포리포프로테인 (a) 발현 조정
WO2017190031A1 (en) 2016-04-28 2017-11-02 Indiana University Research And Technology Corporation Methods and compositions for resolving components of a virus preparation
US11060092B2 (en) 2016-07-13 2021-07-13 Technion Research & Development Foundation Limited Inhibitors of cytoplasmic histone deacetylase 4 complex for treating or preventing vascular or valve calcification
JP2019524787A (ja) 2016-08-03 2019-09-05 エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド Ｔｌｒ９標的治療薬
EP3512602B1 (en) 2016-09-16 2024-03-27 HSF Pharmaceuticals Inhibitors of heat shock factors (hsf) and uses thereof
CN117801075A (zh) 2017-03-15 2024-04-02 北卡罗来纳-查佩尔山大学 多倍体腺相关病毒载体及其制备和使用方法
EP3685168A1 (en) 2017-09-20 2020-07-29 The Trustees Of Indiana University Methods for resolving lipoproteins with mass spectrometry
EP3738137A1 (en) 2018-01-12 2020-11-18 The Trustees of Indiana University Electrostatic linear ion trap design for charge detection mass spectrometry
EP3773743A1 (en) 2018-04-03 2021-02-17 Stridebio, Inc. Virus vectors for targeting ophthalmic tissues
KR20210006357A (ko) 2018-04-03 2021-01-18 스트라이드바이오 인코포레이티드 항체-회피 바이러스 벡터
KR20210007963A (ko) 2018-04-03 2021-01-20 스트라이드바이오 인코포레이티드 항체-회피 바이러스 벡터
CA3100840A1 (en) 2018-06-04 2019-12-12 The Trustees Of Indiana University Apparatus and method for capturing ions in an electrostatic linear ion trap
EP3803953A1 (en) 2018-06-04 2021-04-14 The Trustees of Indiana University Ion trap array for high throughput charge detection mass spectrometry
WO2019236139A1 (en) 2018-06-04 2019-12-12 The Trustees Of Indiana University Interface for transporting ions from an atmospheric pressure environment to a low pressure environment
JP7306727B2 (ja) 2018-06-04 2023-07-11 ザ・トラスティーズ・オブ・インディアナ・ユニバーシティー リアル・タイム分析および信号最適化による電荷検出質量分光分析法
WO2019236143A1 (en) 2018-06-04 2019-12-12 The Trustees Of Indiana University Apparatus and method for calibrating or resetting a charge detector
CA3104113A1 (en) 2018-06-22 2019-12-26 Asklepios Biopharmaceutical, Inc. Vectors for gene delivery that persist within cells
EP3860564A1 (en) 2018-10-04 2021-08-11 University Of Rochester Improvement of glymphatic delivery by manipulating plasma osmolarity
EP3877523A1 (en) 2018-11-09 2021-09-15 Novartis AG Method for reducing the risk of a cardiovascular event with conjugated antisense compounds targeting apo(a)
JP7285023B2 (ja) 2018-11-20 2023-06-01 ザ・トラスティーズ・オブ・インディアナ・ユニバーシティー 単一粒子質量分光分析のためのオービトラップ
CA3118567A1 (en) 2018-12-03 2020-06-11 The Trustees Of Indiana University Apparatus and method for simultaneously analyzing multiple ions with an electrostatic linear ion trap
MX2021011468A (es) 2019-03-21 2021-12-15 Vectores de virus adenoasociados recombinantes.
WO2020219527A1 (en) 2019-04-23 2020-10-29 The Trustees Of Indiana University Identification of sample subspecies based on particle charge behavior under structural change-inducing sample conditions
EP4169535A1 (en) 2019-04-26 2023-04-26 The University of North Carolina at Chapel Hill Methods and compositions for dual glycan binding aav2.5 vector
US20230392163A1 (en) 2019-10-17 2023-12-07 Ginkgo Bioworks Inc. Adeno-associated viral vectors for treatment of niemann-pick disease type c
WO2022093769A1 (en) 2020-10-28 2022-05-05 The University Of North Carolina At Chapel Hill Methods and compositions for dual glycan binding aav2.5 vector
EP4010356A4 (en) 2020-10-28 2023-01-04 The University of North Carolina at Chapel Hill METHODS AND COMPOSITIONS FOR GLYCAN DOUBLE BONDING OF VAA2.5 VECTORS
TW202242124A (zh) 2021-01-14 2022-11-01 美商史崔德生物公司 靶向ｔ細胞之ａａｖ載體
JP2024515626A (ja) 2021-04-16 2024-04-10 アスクレピオス バイオファーマシューティカル， インコーポレイテッド 血液脳関門を横断し低減された液性応答を惹起する合理的ポリプロイドａａｖビリオン
WO2023122720A1 (en) 2021-12-23 2023-06-29 University Of Rochester Compositions and methods for delivery of agents to inner ear
WO2023122719A2 (en) 2021-12-23 2023-06-29 University Of Rochester Csf transport pathway for delivery of agents to inner ear
WO2023150687A1 (en) 2022-02-04 2023-08-10 Ginkgo Bioworks, Inc. Recombinant adeno-associated virus vectors, and methods of use thereof
WO2024040222A1 (en) 2022-08-19 2024-02-22 Generation Bio Co. Cleavable closed-ended dna (cedna) and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4987071A (en) * 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
WO1991003162A1 (en) * 1989-08-31 1991-03-21 City Of Hope Chimeric dna-rna catalytic sequences
US6365730B1 (en) * 1990-06-19 2002-04-02 Gene Shears Pty. Limited DNA-Armed ribozymes and minizymes
CA2093664C (en) * 1990-10-12 2003-07-29 Fritz Eckstein Modified ribozymes
DE4216134A1 (de) * 1991-06-20 1992-12-24 Europ Lab Molekularbiolog Synthetische katalytische oligonukleotidstrukturen
US5652094A (en) * 1992-01-31 1997-07-29 University Of Montreal Nucleozymes
WO1993023569A1 (en) * 1992-05-11 1993-11-25 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting viral replication
JPH07509133A (ja) * 1992-07-17 1995-10-12 リボザイム・ファーマシューティカルズ・インコーポレイテッド 動物疾患の処置のための方法および剤

Also Published As

Publication number Publication date
WO1996009392A1 (en) 1996-03-28
US5599706A (en) 1997-02-04
CA2199727A1 (en) 1996-03-28
AU3720295A (en) 1996-04-09
JPH10506016A (ja) 1998-06-16
EP0782622A1 (en) 1997-07-09
US5877022A (en) 1999-03-02

Similar Documents

Publication Publication Date Title
MX9702204A (es) Tratamiento con ribozimas de enfermedades o condiciones relacionadas con niveles de lipoproteina (a) [lp(a)] en plasma, inhibiendo apolipoproteina (a) [apo(a)].
BR9908280A (pt) Inibidores de enzimas de fosfolipase
AU7321598A (en) Use of cholinesterase inhibitors to treat disorders of attention
AU3767997A (en) Acylpyrroldicarboxylic acids and acylindoldicarboxylic acids and their derivatives and inhibitors of the cytosolic phospholipase a2
ATE230600T1 (de) Verwendung eines thienotriazoldiazepins zur erhöhung des apolopoproteins a-i niveaus
DE60024660D1 (de) Menschliche rnase h und entsprechende oligonukleotidverbindungen
WO1997006662A3 (en) Inverted chimeric and hybrid oligonucleotides
BR9607474A (pt) Processos para liquefazer composições de amido e para desativar uma enzima hidrolisadora e composição de matéria
MX9801093A (es) Inhibidores de la proteinasa c para el tratamiento de enfermedades relacionadas con la sobreproduccion de colagena.
MY129998A (en) Saccharin derivative proteolytic enzyme inhibitors
BR0112800A (pt) Utilização de um inibidor de lìpases e de um sequestrante de ácido de bìlis farmaceuticamente aceitáveis e processo para a prevenção e tratamento de enfermidades associadas com altos nìveis de colesterol de plasma
GR3024597T3 (en) 7-deazapurine modified oligonucleotides
BR9904449A (pt) Processo para o preparo de ácido pantotênico através de amplificação de sequências de nucleotìdeos, as quais codificam a redutase de cetopantoato
DK0635053T3 (da) Rhamnogalacturonan-acetylesterase fra Aspergillus aculeatus
ES2191030T3 (es) Enzima que presenta actividad pectina metilesterasa.
WO1998032846A3 (en) Enzymatic nucleic acid treatment of diseases or conditions related to levels of c-fos
NZ334968A (en) Esterases derived from Aspergillus
ATE226254T1 (de) Reagenz zur behandlung von arthritischen zustaenden
ATE212859T1 (de) C1-esterasehemmer zur verringerung von myokardschäden bei akutem herzinfarkt
WO1999002673A3 (en) Antisense oligonucleotide sequences as inhibitors of microorganisms
WO2001057206A3 (en) Method and reagent for the inhibition of checkpoint kinase-1 (chk 1) enzyme
EP0489839A4 (en) Novel hydrolytic enzyme inhibitors and substrates and assays, methods and kits embodying same
EP0794256A3 (en) Method for culturing microorganisms having methanol metabolic pathway
AU9802798A (en) Gas treating solution corrosion inhibitor
AU5868698A (en) Specific pancreatic lipase inhibitors and their applications

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees